Monograph Details
|
|
Central Nervous System
> Anxiety/OCD
|
|
KLONOPIN |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
CIV |
| Pharmacological Class |
|
Benzodiazepine. |
| Generic Name |
|
Clonazepam 0.5mg+, 1mg, 2mg; tabs; +scored. |
| Also |
|
• KLONOPIN WAFERS
|
| Indications |
|
Panic disorder. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
>18yrs: initially 0.25mg twice daily; after 3 days increase to 1mg/day; then may increase every 3 days by 0.125–0.25mg twice daily; max 4mg/day. Wafers: dissolve in mouth; swallow with or without water. |
| Contraindications |
|
Significant liver disease. Acute narrow-angle glaucoma. |
| Precautions |
|
Chronic respiratory disease. Renal impairment. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Elderly. Labor & delivery, pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A (eg, azole antifungals). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, phenobarbital). Wafers may be antagonized by propantheline. |
| Adverse Reactions |
|
CNS effects (esp. depression), hypersalivation, liver disorders, GI upset, blood dyscrasias, paradoxical reactions. |
| How Supplied |
Tabs—100
Wafers—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
